Decrease of Inhibitory Synaptic Currents of Locus Coeruleus Neurons Via Orexin Type 1 Receptors in the Context of Naloxone-induced Morphine Withdrawal
Overview
Affiliations
Acute opioid withdrawal syndrome is a series of neurological symptoms caused by the abrupt cessation of the chronic administration of opioids such as morphine. The locus coeruleus (LC) in the brain stem receives a dense projection of orexinergic fibers from the hypothalamus and is a candidate site for the expression of the somatic aspects of morphine withdrawal. Previous studies have shown that orexin-A contributes to the behavioral symptoms of naloxone-induced morphine withdrawal, partly by reducing the activity of GABAergic neurons, suggesting that orexin-A may negatively modulate fast GABAergic neurotransmission during morphine withdrawal. We used whole-cell patch-clamp recordings of LC neurons in brainstem slices to investigate the effect of orexin-A on bicuculline-sensitive GABAergic inhibitory postsynaptic currents (IPSCs) during naloxone-induced morphine withdrawal. Male Wistar rats (P14-P21) were given morphine (20 mg/kg, i.p.) daily for seven consecutive days to create dependency on the drug. The application of naloxone (1 µM) to brain slices of morphine-treated rats reduced the amplitude of evoked IPSCs (eIPSCs) as well as spontaneous IPSCs (sIPSCs) frequency but did not change sIPSCs amplitude. Orexin-A (100 nM) significantly enhanced the suppressive effect of naloxone on eIPSCs amplitude and sIPSCs frequency but had no effect on the presence of the orexin type 1 receptor (OX1R) antagonist, SB-334867. Orexin-A alone had no significant effect on eIPSCs and sIPSCs in the absence of naloxone. In summary, our results show that orexin-A, via OX1R, potentiates the suppressive effect of naloxone on GABAergic IPSCs of LC neurons in morphine-treated rats. We conclude that orexins may have a critical role in regulating GABAergic neurotransmission to LC neurons during naloxone-induced morphine withdrawal.
Physiological Role of Orexinergic System for Health.
Villano I, La Marra M, Di Maio G, Monda V, Chieffi S, Guatteo E Int J Environ Res Public Health. 2022; 19(14).
PMID: 35886210 PMC: 9323672. DOI: 10.3390/ijerph19148353.
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
Chalhoub R, Kalivas P Drugs. 2020; 80(15):1509-1524.
PMID: 32776315 PMC: 7541583. DOI: 10.1007/s40265-020-01373-1.
Davoudi M, Vijeepallam K, Azizi H, Mirnajafi-Zadeh J, Semnanian S J Neural Transm (Vienna). 2019; 126(11):1425-1435.
PMID: 31493096 DOI: 10.1007/s00702-019-02064-2.